U.S. Patent 10,933,020: Xanomeline-Trospium Bead Composition, Claim Scope and Patent Landscape

U.S. Patent No. 10,933,020 protects oral dosage forms combining xanomeline and trospium in separate multiparticulate bead populations. The strongest commercial claims cover capsules containing xanomeline tartrate beads and trospium chloride beads, including specified bead sizes, excipient compositions, dissolution performance, pharmacokinetic profiles, dosage strengths and manufacturing steps.

The patent is central to the intellectual-property position for KarXT, marketed in the United States as Cobenfy. It is a small-molecule formulation patent, not a biologic patent. Biosimilar provisions do not apply; a future challenger would generally use the abbreviated new drug application pathway and could raise a Paragraph IV certification against listed patents.

What does U.S. Patent 10,933,020 protect?

The patent contains five principal claim groups:

Claim group	Claims	Protected subject matter
Multiparticulate composition	1-39	Separate xanomeline and trospium beads, including particle size, composition and capsule strengths
Pharmacokinetic composition	40-42	Xanomeline-trospium products defined by in-vivo exposure and Tmax parameters
Therapeutic method	43-44	Treatment of muscarinic disorders using the claimed composition
Impurity limitation	45	Xanomeline-containing composition with less than 0.5 wt.% of a specified impurity
Manufacturing method	46	Mixing xanomeline beads with trospium beads

The independent composition claim requires two distinct populations of beads:

A plurality of xanomeline beads with cores containing xanomeline or a salt.
A plurality of trospium beads with cores containing a trospium salt.

A product containing a homogeneous powder blend, a single co-processed particle population or a conventional bilayer tablet would not literally satisfy claim 1 unless its structure met the claimed bead limitations.

How broad is claim 1 of U.S. Patent 10,933,020?

Claim 1 is structurally broad but technologically focused. It does not require:

Xanomeline tartrate specifically;
Trospium chloride specifically;
Particular excipients;
A capsule;
A stated dose;
A specified dissolution rate;
A particular pharmacokinetic profile; or
A particular disease indication.

The claim does require bead populations with cores containing the two active ingredients. “A plurality” normally requires more than one bead, while the claim does not state a minimum bead count. The absence of a required capsule means that tablets, sachets or other oral dosage forms could potentially fall within the claim if they contain the required bead populations.

The phrase “core comprising” generally leaves room for additional core materials and surrounding layers. The claim therefore reaches formulations in which the active ingredient is part of a pellet, coated bead, extruded particle or other multiparticulate structure, subject to the patent’s specification and claim-construction record.

What formulations are protected by the dependent claims?

Claims 11-30 provide the most detailed formulation protection.

Xanomeline bead formulation

The xanomeline bead claims cover xanomeline tartrate with microcrystalline cellulose and talc:

Parameter	Claimed range	Narrow disclosed value
Xanomeline tartrate	30-80 wt.%	66 wt.%
Microcrystalline cellulose	15-65 wt.%	33.5 wt.%
Talc	0-2 wt.%	0.5 wt.%

Claim 19 combines the three narrow values: 66 wt.% xanomeline tartrate, 33.5 wt.% microcrystalline cellulose and 0.5 wt.% talc.

Trospium bead formulation

The trospium bead claims cover trospium chloride with microcrystalline cellulose, lactose monohydrate and talc:

Parameter	Claimed range	Narrow disclosed value
Trospium chloride	8-35 wt.%	17.7 wt.%
Microcrystalline cellulose	25-80 wt.%	46.8 wt.%
Lactose monohydrate	15-70 wt.%	35 wt.%
Talc	0-2 wt.%	0.5 wt.%

Claim 30 combines the narrow values. This is likely the most formulation-specific composition claim in the set and would be relevant to a capsule using substantially the disclosed bead recipes.

What bead sizes and release properties are covered?

Claims 2-5 define bead size:

Bead population	Broad size range	Narrow size range
Xanomeline beads	0.425-1.18 mm	0.6-0.85 mm
Trospium beads	0.425-1.18 mm	0.6-0.85 mm

Claims 7 and 8 add rapid dissolution requirements. The combined bead populations must release more than approximately 95% within 45 minutes, with claim 8 narrowing the period to approximately 20 minutes.

These limitations create both infringement and validity issues. A challenger may contest:

The measurement method used to determine bead size;
Whether size refers to nominal, average, sieve or particle-size distribution;
The dissolution medium, apparatus, agitation and sampling method;
Whether the 95% requirement applies separately to each active ingredient or to the combined system; and
Whether “about” creates an enforceable tolerance around the stated values.

The specification and prosecution history would be important in determining how these terms are construed.

Which Cobenfy dosage strengths are covered?

Claims 31-39 cover a capsule containing both bead populations. The listed strengths are:

Claim	Xanomeline free base	Trospium chloride
32	25 mg	10 mg
33	50 mg	20 mg
34	50 mg	10 mg
35	75 mg	10 mg
36	75 mg	20 mg
37	125 mg	20 mg
38	125 mg	30 mg
39	125 mg	40 mg

These claims calculate xanomeline by free-base equivalent while identifying trospium by salt amount. A commercial product using different labeling conventions could still infringe if the underlying quantities satisfy the claim limitations.

Cobenfy was approved by the FDA on September 26, 2024, for the treatment of schizophrenia in adults. The product combines xanomeline, a muscarinic receptor agonist, with trospium chloride, a peripheral muscarinic antagonist. FDA-approved labeling describes Cobenfy as an oral capsule product with titrated dosing rather than as a conventional single active-ingredient formulation (FDA, 2024).

What do the pharmacokinetic claims cover?

Claims 9 and 10 require administration of the composition for at least seven days at 20 mg trospium twice daily and specify:

Mean trospium Cmax of 7,850 ± 3,360 pg/mL; and
Mean trospium AUC0-12 of 41,900 ± 15,500 hr·pg/mL.

Claims 40-42 define the product through a plasma profile:

Median xanomeline Tmax of two hours;
Median trospium Tmax of one hour;
Dose-normalized xanomeline Cmax of 48.5-121.3 pg/mL/mg;
Dose-normalized trospium Cmax of 156-375 pg/mL/mg;
Dose-normalized xanomeline AUC0-12 of 263-577 hr·pg/mL/mg; and
Dose-normalized trospium AUC0-12 of 881-2,024 hr·pg/mL/mg.

These claims are difficult to assess from product labeling alone. Infringement would depend on study design, patient population, dose, sampling schedule, analytical methods and statistical treatment. They may create a material barrier where a competing formulation is chemically different but produces a substantially equivalent plasma profile.

They also present potential enforcement challenges because pharmacokinetic results can vary across subjects and studies. A challenger could argue that the claimed ranges lack adequate written description, enablement or reproducibility if the patent does not support the full breadth of the claimed profiles.

What methods of treatment and manufacture are protected?

Claim 43 covers administration of claim 1 to treat a disorder ameliorated by muscarinic receptor activation. Claim 44 lists:

Schizophrenia;
Alzheimer’s disease;
Parkinson’s disease;
Depression;
Movement disorders;
Pain;
Drug addiction;
Tauopathy; and
Synucleinopathy.

The method claims are narrower than a composition claim because they require administration of a composition that falls within claim 1. A generic product could avoid literal infringement of claim 43 if it does not use the claimed bead architecture, although induced-infringement and label-content issues would remain relevant.

Claim 46 covers admixing xanomeline beads with trospium beads. It may reach contract manufacturers and finished-dose manufacturers that use the claimed assembly step, depending on the actual process and the doctrine of divided infringement.

Claim 45 separately limits a specified xanomeline-related impurity to less than 0.5 wt.%. This claim is important for manufacturing control and analytical comparability. A competitor may avoid it through a different impurity profile while still encountering claims 1-44.

When does U.S. Patent 10,933,020 lose exclusivity?

The patent issued on March 2, 2021. Its enforceable term is generally measured from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension and terminal disclaimers. The claim set alone does not establish the legally operative expiration date.

Public patent-family records associate the patent with the xanomeline-trospium development program and Karuna-related ownership. The patent’s effective exclusivity period is expected to extend into the late 2030s, but the exact expiration date should be taken from the USPTO patent-term calculation and the FDA Orange Book listing rather than inferred from the issue date.

FDA regulatory exclusivity is separate from patent exclusivity. Cobenfy received approval in 2024. Its five-year new chemical entity exclusivity would ordinarily run from approval, subject to the precise regulatory classification and any applicable exclusivity provisions. That period does not extend the patent term.

What is the Orange Book status of U.S. Patent 10,933,020?

U.S. Patent 10,933,020 is associated with the Cobenfy xanomeline-trospium product and is relevant to Orange Book-based generic challenges. The critical regulatory questions are:

Whether the patent is listed against the approved Cobenfy drug product;
Which approved strengths and dosage forms are covered;
Whether the listing includes composition, method-of-use or other claim categories;
Whether a later ANDA applicant must provide a Paragraph IV certification; and
Whether the NDA holder has sued within the statutory 45-day period after receiving notice.

A Paragraph IV certification would allege that the patent is invalid, unenforceable or not infringed. A timely patent suit can trigger a 30-month stay of final ANDA approval, subject to statutory exceptions and court action. The patent number alone does not establish whether a particular generic applicant has filed a Paragraph IV certification or whether litigation has commenced.

Which companies are challenging the Cobenfy patent estate?

No biosimilar pathway applies because xanomeline and trospium are small molecules. The relevant challengers would be generic-drug companies filing ANDAs.

Publicly confirmed Paragraph IV challenges, patent litigation, and settlement agreements should be evaluated by reviewing FDA Orange Book updates, ANDA litigation complaints, court dockets and SEC filings. A market entrant cannot assume that the absence of a publicly reported case eliminates risk. A filing may remain confidential until litigation is initiated or an Orange Book update is published.

The principal commercial patent holder was Karuna Therapeutics. Bristol Myers Squibb completed its acquisition of Karuna in March 2024 and became the commercial owner of the Cobenfy business and related Karuna assets (Bristol Myers Squibb, 2024).

How strong is the patent estate for Cobenfy?

The estate is stronger when a product uses the disclosed multiparticulate architecture than when it merely combines the two active ingredients.

Risk area	Relative exposure
Separate xanomeline and trospium beads	High
Disclosed bead-size ranges	High if reproduced
Specific excipient recipes	Moderate to high
Listed capsule strengths	High for matching products
PK profile claims	Fact-dependent
Treatment of schizophrenia	Dependent on composition infringement
Impurity claim	Manufacturing-specific
Mixing process	High for direct process replication
Homogeneous powder or unrelated dosage form	Lower under literal claim analysis

The patent does not claim every xanomeline-trospium combination. It is directed to a particular delivery architecture designed to manage the pharmacology of centrally active xanomeline and peripherally acting trospium.

What generic entry risks exist?

A generic launch strategy would likely involve one or more of the following:

A Paragraph IV challenge to the bead-composition claims;
A noninfringement design using a different particle architecture;
Different excipients or drug-loading levels;
A modified-release or alternative-release profile;
A different capsule strength;
A challenge to the PK limitations;
A process that avoids admixing the two claimed bead populations; or
A Section viii statement carving out method-of-use claims where permitted.

The highest-risk design would replicate the two bead populations, the 0.6-0.85 mm particle sizes, the disclosed excipient percentages, the rapid dissolution profile and the listed capsule strengths.

How does the patent compare with competing patent barriers?

Cobenfy’s primary barrier is formulation and product architecture. That differs from products protected mainly by:

Compound patents covering a new chemical entity;
Polymorph or salt patents;
Extended-release formulation patents;
Device or delivery-system patents;
Method-of-use patents; or
Manufacturing and impurity-control patents.

Because xanomeline was known before the Cobenfy development program, the commercial protection depends heavily on formulation, combination, pharmacokinetic and regulatory exclusivity layers. The combination of those layers can delay generic entry even if one claim group is invalidated.

Key Takeaways

U.S. Patent 10,933,020 centers on separate xanomeline and trospium bead populations in an oral dosage form.
Claims 19 and 30 protect narrow bead recipes using xanomeline tartrate or trospium chloride with microcrystalline cellulose, lactose monohydrate and talc.
Claims 31-39 cover multiple capsule strengths, including combinations listed in the patent.
Claims 7-10 and 40-42 add dissolution and pharmacokinetic limitations.
Claims 43-44 cover treatment of muscarinic disorders, including schizophrenia.
Claim 45 targets a specified xanomeline-related impurity.
Claim 46 covers admixing the two bead populations during manufacture.
Cobenfy is FDA-approved for adult schizophrenia and is marketed by Bristol Myers Squibb following its acquisition of Karuna.
Biosimilar risk is irrelevant; any abbreviated-approval challenge would involve an ANDA and potentially a Paragraph IV certification.
The strongest infringement risk is for a generic that copies the bead architecture, particle sizes, excipient composition and capsule strengths.

FAQs

Does U.S. Patent 10,933,020 cover xanomeline alone?

No. The principal composition claim requires both xanomeline beads and trospium beads. Other claims separately impose pharmacokinetic, impurity, treatment or manufacturing limitations.

Can a tablet infringe U.S. Patent 10,933,020?

Potentially. Claim 1 does not require a capsule. A tablet containing separate xanomeline and trospium bead populations could fall within the claim if all structural limitations are met.

Does the patent cover trospium chloride by itself?

No. The claimed composition requires xanomeline or a xanomeline salt together with a trospium salt. Trospium chloride alone is outside the principal combination claim.

Are Cobenfy dose titration regimens protected by this patent?

The patent claims several capsule strengths and treatment methods, but the supplied claims do not independently claim every titration schedule. Coverage depends on the composition administered and the specific method limitations.

Can a generic avoid the patent by changing the excipients?

Changing excipients may avoid narrow formulation claims such as claims 19 and 30. It may not avoid claim 1 if the generic still uses separate xanomeline and trospium bead populations.

References

Bristol Myers Squibb. (2024). Bristol Myers Squibb completes acquisition of Karuna Therapeutics.
U.S. Food and Drug Administration. (2024). Cobenfy (xanomeline and trospium chloride) prescribing information.
U.S. Patent and Trademark Office. (2021). U.S. Patent No. 10,933,020, pharmaceutical compositions comprising xanomeline and trospium.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol-myers	COBENFY	trospium chloride; xanomeline tartrate	CAPSULE;ORAL	216158-001	Sep 26, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			TREATMENT OF SCHIZOPHRENIA IN ADULTS	⤷ Start Trial
Bristol-myers	COBENFY	trospium chloride; xanomeline tartrate	CAPSULE;ORAL	216158-002	Sep 26, 2024		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y			TREATMENT OF SCHIZOPHRENIA IN ADULTS	⤷ Start Trial
Bristol-myers	COBENFY	trospium chloride; xanomeline tartrate	CAPSULE;ORAL	216158-003	Sep 26, 2024		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y			TREATMENT OF SCHIZOPHRENIA IN ADULTS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019346626	⤷ Start Trial
Australia	2022224813	⤷ Start Trial
Australia	2024267020	⤷ Start Trial
Brazil	112021005802	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,933,020

Which drugs does patent 10,933,020 protect, and when does it expire?

Summary for Patent: 10,933,020